AstraZeneca PLC (AZN.L)
| Previous close | 8,348.00 |
| Open | 8,390.00 |
| Bid | 8,338.00 x 0 |
| Ask | 8,341.00 x 0 |
| Day's range | 8,337.00 - 8,409.00 |
| 52-week range | 6,499.80 - 10,120.00 |
| Volume | 577,439 |
| Avg. volume | 2,684,887 |
| Market cap | 109.485B |
| Beta (5Y monthly) | 0.21 |
| PE ratio (TTM) | 38.84 |
| EPS (TTM) | 214.70 |
| Earnings date | 29 Jul 2021 |
| Forward dividend & yield | 2.07 (2.48%) |
| Ex-dividend date | 25 Feb 2021 |
| 1y target est | 78.83 |
- Editor's pickYahoo Finance Video
Ethics have been ‘pushed to the back’ amid COVID-19: Doctor
The Institute for Antiracism in Medicine Co-Founder & The University of Illinois College of Medicine Assistant Professor of Clinical & Family Medicine Dr. Brittani James joins Yahoo Finance Live to discuss the latest updates amid the COVID-19 pandemic.
- The Telegraph
AstraZeneca Covid-19 treatment fails to help those exposed to virus
An experimental antibody treatment designed to stop people developing Covid-19 after being exposed to the virus has failed clinical trials, dealing a blow to Britain's hopes of developing a new weapon to fight coronavirus. Anglo-Swedish drugmaker AstraZeneca gave an antibody drug to unvaccinated adults who had been exposed to Covid-19 within the past eight days. Antibody treatments are meant to work by pumping patients with antibodies to boost their immune system and stop them from developing a
- Yahoo Finance UK
AstraZeneca's 'Storm Chaser' COVID trial misses goal but offers some hope
AZD7442 failed to meet the main goal of stopping people developing symptomatic COVID-19 but did offer some hope that it could help people who had not yet come into contact with the virus.
